Announcement: Dr. Qingping Feng appointed as the Richard & Jean Ivey Fund Chair in Molecular ToxicologyI am pleased to announce Dr. Qingping Feng has been appointed as the Richard & Jean Ivey Fund Chair in Molecular Toxicology at the Schulich School of Medicine & Dentistry, Western University effective August 1, 2017 to July 31, 2022.
Dr. Feng earned a bachelor of medicine and master of science at the Southeast University Medical School in Nanjing, China. He then completed a PhD at the University of Gothenburg in Sweden.
Currently, Dr. Feng is appointed as a professor in the Departments of Physiology and Pharmacology and Medicine at the Schulich School of Medicine & Dentistry. The research in the Feng laboratory seeks to understand pathophysiological mechanisms of heart failure and molecular regulation of fetal heart development.
The Feng lab utilizes a variety of scientific approaches, ranging from cellular and molecular biology to in vivo physiology and pharmacology. Their current research is focused on fetal heart development, maternal-fetal toxicology and heart failure post myocardial infarction. Recently, they have demonstrated that oxidative stress is an important molecular mechanism in the teratogenic effect of maternal diabetes on the fetal heart. Another area of their research is the study of signal transduction mechanisms in cardiomyocytes in sepsis. The studies are currently funded by Canadian Institutes of Health Research (CIHR), the Heart & Stroke Foundation of Canada and Natural Sciences and Engineering Research Council (NSERC).
Dr. Feng has created an excellent lab environment for trainees by providing opportunities to perform research using multifaceted approaches. He has successfully trained nine masters, 10 doctoral students and 15 postdoctoral trainees. Several of his trainees are now independent investigators in Canada and abroad. He has published 110 peer-reviewed original papers, many in excellent impact journals including Circulation, European Heart Journal, Diabetes, Cardiovascular Research and Critical Care Medicine. In recognition of his accomplishments, Dr. Feng has been supported by a Research Career Award from the CIHR and Innovative Medicines Canada (Rx&D) Partnership Program from 1999 to 2005 and a Career Investigator Award from the Heart and Stroke Foundation of Ontario from 2005 to2015.
Please join me in congratulating Dr. Feng on his appointment.
Dr. Michael J. Strong
Dean, Schulich School of Medicine & Dentistry
Distinguished University Professor
Arthur J Hudson Chair in ALS Research
Scientist, Robarts Research Institute